| Title: |
Ki67 and breast cancer mortality in women with invasive breast cancer. |
| Authors: |
Probert, Jake; Dodwell, David; Broggio, John; Charman, Jackie; Dowsett, Mitch; Kerr, Amanda; McGale, Paul; Taylor, Carolyn; Darby, Sarah C; Mannu, Gurdeep S |
| Source: |
JNCI Cancer Spectrum; Oct2023, Vol. 7 Issue 5, p1-10, 10p |
| Abstract: |
Background The percentage of cells staining positive for Ki67 is sometimes used for decision-making in patients with early invasive breast cancer (IBC). However, there is uncertainty regarding the most appropriate Ki67 cut points and the influence of interlaboratory measurement variability. We examined the relationship between breast cancer mortality and Ki67 both before and after accounting for interlaboratory variability and 8 patient and tumor characteristics. Methods A multicenter cohort study of women with early IBC diagnosed during 2009-2016 in more than 20 NHS hospitals in England and followed until December 31, 2020. Results Ki67 was strongly prognostic of breast cancer mortality in 8212 women with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative early IBC (P trend |
| : |
Copyright of JNCI Cancer Spectrum is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |